Articles tagged with “targeted-therapy”

Beqalzi (Sonrotoclax) FDA Approval: BCL-2 Inhibitor for MCL

Examine the FDA accelerated approval of Beqalzi (sonrotoclax), the first BCL-2 inhibitor for relapsed mantle cell lymphoma, including efficacy and safety data.

40 min read

5/4/2026

beqalzi sonrotoclax mantle cell lymphoma mcl bcl-2 inhibitor hematologic oncology fda approval targeted therapy

Daraxonrasib RAS(ON) Inhibitor: Pancreatic Cancer Results

Analyze the Phase 3 RASolute-302 trial results for daraxonrasib, a novel RAS(ON) inhibitor demonstrating significant survival benefit in pancreatic cancer.

40 min read

4/28/2026

daraxonrasib rmc-6236 pancreatic cancer ras(on) inhibitors kras mutations rasolute-302 targeted therapy oncology clinical trials

Biomarker Testing Coordination Services: An Oncology Guide

Updated 2026 guide to biomarker testing coordination services in oncology. Covers navigator roles, FDA companion diagnostic reclassification, liquid biopsy adoption, NCCN guideline updates, and AI-driven diagnostics for precision medicine.

40 min read

11/16/2025

biomarker testing precision medicine oncology patient navigation lab coordination nsclc targeted therapy